The Pulmonary Hypertension Association (PHA) announces the dates and cities for two PHA on the Road: PH Patients and Families Education Forums for 2018. Forums are scheduled in Long Beach, Calif., September 29, and Milwaukee, October 27. PHA on the Road, a program of the PHA Medical Education Fund,* provides a unique opportunity for people with PH, their families and caregivers to meet others living with PH in their region and to learn from PH expert physicians and health care professionals. These forums feature interactive presentations, Q&A sessions and networking opportunities, so that people with PH may learn more about the key elements of their disease, including: required tests, treatment options, current PH research, the importance of a healthy diet and exercise; and how to build a network of support. Topics will include:
- PH 101: the journey to diagnosis and treatment.
- Balancing sodium and fluid intake.
- Debunking PH myths and misconceptions.
- Managing side effects of PH medications.
- Prostacyclin therapies for WHO Group 1 PH (pulmonary arterial hypertension, or PAH).
- PH research: how to get involved and make a difference.
Long Beach, Calif.
Saturday, Sept. 29, 2018
8:30 a.m. to 3:30 p.m. PDT
Renaissance Long Beach Hotel
111 E. Ocean Blvd.
Long Beach, CA 90802
Saturday, Oct. 27, 2018
8:30 a.m. to 3:30 p.m. CDT
Four Points by Sheraton
5311 South Howell Ave.
Milwaukee, WI 5320
Led by national co-chairs, Wendy Hill, M.S.N., NP-C, Cedars-Sinai Medical Center; and Thenappan Thenappan, M.D., University of Minnesota, PHA on the Road is designed to help patients and their families learn all that they need to know about living their best lives with PH.
PHA on the Road is a free event and includes complimentary childcare for ages 3-17, parking, breakfast, lunch, coffee and snacks. Learn more and read testimonials from 2017 PHA on the Road attendees at www.PHAontheRoad.org. We hope to see you “on the Road!”
*PHA on the Road is a program of the PHA Medical Education Fund, made possible through educational grants from our supporters (Actelion Pharmaceuticals US, Inc., United Therapeutics Corporation and Gilead Sciences, Inc.)